ovarian serous surface papillary adenocarcinoma | ClinicalTrials HQ

View definition

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Adnexal Diseases, Brenner tumor, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Urogenital Diseases, Urogenital Neoplasms, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, fibroepithelial neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian Brenner tumor, ovarian cancer, ovarian carcinosarcoma, ovarian clear cell cystadenocarcinoma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian mucinous cystadenocarcinoma, ovarian seromucinous carcinoma, ovarian serous cystadenocarcinoma, ovarian serous surface papillary adenocarcinoma, undifferentiated ovarian carcinoma	Active, not recruiting	Phase 2	2026-09-10		NCT02101775
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, fallopian tube carcinoma, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, ovarian endometrioid adenocarcinoma, ovarian serous adenocarcinoma, ovarian serous surface papillary adenocarcinoma, primary peritoneal serous adenocarcinoma, skin disorder, triple-negative breast carcinoma	Active, not recruiting	Phase 1 / Phase 2	2026-07-14		NCT01116648